AU2022418280A1 - Use of aminopyrazole compounds - Google Patents

Use of aminopyrazole compounds Download PDF

Info

Publication number
AU2022418280A1
AU2022418280A1 AU2022418280A AU2022418280A AU2022418280A1 AU 2022418280 A1 AU2022418280 A1 AU 2022418280A1 AU 2022418280 A AU2022418280 A AU 2022418280A AU 2022418280 A AU2022418280 A AU 2022418280A AU 2022418280 A1 AU2022418280 A1 AU 2022418280A1
Authority
AU
Australia
Prior art keywords
compound
use according
formula
animal
jak
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022418280A
Other languages
English (en)
Inventor
Linda HORSPOOL
Timothy Kowalski
Christina MÖLLER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intervet International BV
Original Assignee
Intervet International BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet International BV filed Critical Intervet International BV
Publication of AU2022418280A1 publication Critical patent/AU2022418280A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2022418280A 2021-12-24 2022-12-23 Use of aminopyrazole compounds Pending AU2022418280A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21217736 2021-12-24
EP21217736.4 2021-12-24
PCT/EP2022/087698 WO2023118555A1 (en) 2021-12-24 2022-12-23 Use of aminopyrazole compounds

Publications (1)

Publication Number Publication Date
AU2022418280A1 true AU2022418280A1 (en) 2024-06-13

Family

ID=79025165

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022418280A Pending AU2022418280A1 (en) 2021-12-24 2022-12-23 Use of aminopyrazole compounds

Country Status (9)

Country Link
US (1) US20250049775A1 (https=)
EP (1) EP4452970A1 (https=)
JP (1) JP2024545293A (https=)
KR (1) KR20240124925A (https=)
CN (1) CN118541364A (https=)
AU (1) AU2022418280A1 (https=)
CA (1) CA3242449A1 (https=)
MX (1) MX2024007863A (https=)
WO (1) WO2023118555A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4208157A1 (en) 2020-09-04 2023-07-12 Elanco Us Inc. Palatable formulations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK286640B6 (sk) 1998-06-19 2009-03-05 Pfizer Products Inc. Pyrol [2,3-d] pyrimidínová zlúčenina, jej použitie na výrobu liečiva, farmaceutická kompozícia s jej obsahom, použitie jej kombinácie s ďalšími činidlami a súpravy s jej obsahom na výrobu liečiva
KR101335843B1 (ko) 2008-08-20 2013-12-02 조에티스 엘엘씨 피롤로[2,3-ｄ]피리미딘 화합물
CA2849168A1 (en) 2011-09-22 2013-03-28 Merck Sharp & Dohme Corp. Cycloalkylnitrile pyrazole carboxamides as janus kinase inhibitors
WO2014146246A1 (en) 2013-03-19 2014-09-25 Merck Sharp & Dohme Corp. Cycloalkyl nitrile pyrazolo pyridones as janus kinase inhibitors
JP7116063B2 (ja) 2016-12-14 2022-08-09 インターベット インターナショナル ベー． フェー． 選択的ヤヌスキナーゼ阻害剤としてのアミノピラゾール類
KR20220119024A (ko) * 2019-12-20 2022-08-26 인터벳 인터내셔널 비.브이. 피라졸 제약 조성물

Also Published As

Publication number Publication date
WO2023118555A1 (en) 2023-06-29
KR20240124925A (ko) 2024-08-19
EP4452970A1 (en) 2024-10-30
US20250049775A1 (en) 2025-02-13
CN118541364A (zh) 2024-08-23
JP2024545293A (ja) 2024-12-05
CA3242449A1 (en) 2023-06-29
MX2024007863A (es) 2024-08-30

Similar Documents

Publication Publication Date Title
JP2025092508A (ja) デクスメデトミジン製剤を使用する睡眠障害の予防または治療
JP6668045B2 (ja) ドラベ症候群を処置するための選択的５−ｈｔ受容体アゴニストおよびアンタゴニスト
US20240277673A1 (en) Methods of treating behavior alterations
ES2750662T3 (es) Orvepitant para el tratamiento del prurito crónico
US20250049775A1 (en) Use of aminopyrazole compounds
US7989479B2 (en) Use of a p38 kinase inhibitor for treating psychiatric disorders
EP2080515A1 (de) Geschmacksstoffhaltige Arzneimittelformulierungen mit verbesserten pharmazeutischen Eigenschaften
JP2017507190A (ja) グラピプラント組成物およびその使用方法
JP7500600B2 (ja) プレガバリン製剤およびその使用
RU2799049C2 (ru) Способы лечения изменений поведения
CA3071804C (en) Use of a kdm1a inhibitor in the treatment of behavior alterations
HK40122445A (en) Methods of treating behavior alterations
CN111432813A (zh) 用于预防、减轻、或治疗精神分裂症的包含氨基甲酸酯化合物的共混物